SNORD113-8: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD113-8

NCBI ID: G767568

SNORD113-8

Other Name(s): Small nucleolar RNA, C/D box 113-8 | small nucleolar RNA, C/D box 113-8 | 14q(I-8)

SNORD113-8: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to help maintain the stability of the nuclear genome by participating in the repair of DNA damage and the degradation of RNA derived from DNA repair. MBN008881

SnORD113-8 is a specific snRNA molecule that is of particular interest due to its function in regulating gene expression and its potential as a drug target. The C/D box 113-8 region of SNORD113-8 is composed of 21 amino acids and has been shown to play a critical role in the regulation of gene expression.

The Potential Role of SNORD113-8 as a Drug Target

The regulation of gene expression is a critical aspect of cellular biology and is crucial for the development and maintenance of healthy tissues. SNORD113-8 has been shown to play a role in regulating gene expression by binding to specific DNA sequences and participating in the regulation of RNA polymerase II.

SNORD113-8 has also been shown to be a potential drug target due to its role in the development of neurodegenerative diseases. The neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and are associated with the development of significant cognitive impairments.

The regulation of gene expression by SNORD113-8 has been shown to be involved in the development and progression of neurodegenerative diseases. By binding to specific DNA sequences and regulating the activity of RNA polymerase II, SNORD113-8 has been shown to play a role in the regulation of gene expression that is critical for the development and progression of neurodegenerative diseases.

The Potential Role of SNORD113-8 as a Biomarker

SNORD113-8 has also been shown to be a potential biomarker for a variety of diseases. The regulation of gene expression by SNORD113-8 is known to be involved in the development and progression of neurodegenerative diseases, which are characterized by the progressive loss of brain cells.

SNORD113-8 has been shown to be involved in the regulation of gene expression that is critical for the development and progression of neurodegenerative diseases. By binding to specific DNA sequences and regulating the activity of RNA polymerase II, SNORD113-8 has been shown to play a role in the regulation of gene expression that is critical for the development and progression of neurodegenerative diseases.

Conclusion

In conclusion, SNORD113-8 is a potential drug target and biomarker for small nucleolar RNA. The regulation of gene expression by SNORD113-8 is known to play a critical role in the development and progression of neurodegenerative diseases and is of particular interest as a potential drug target and biomarker. Further research is needed to fully understand the role of SNORD113-8 in the regulation of gene expression and its potential as a drug target and biomarker.

Protein Name: Small Nucleolar RNA, C/D Box 113-8

The "SNORD113-8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD113-8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets